Recruiting

Observational Study

Sponsor:

Anova Enterprises, Inc

Code:

NCT05013944

Conditions

Infectious Disease

Neoplasms

Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89)

Endocrine, Nutritional and Metabolic Diseases (E00-E89)

Mental and Behavioural Disorders

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The objective of this study is the development, implementation and management of a registry of patient data that captures clinically meaningful, real-world, data on the diagnosis, nature, course of infection, treatment(s) and outcomes in patients with complex disease globally.

Conditions

Infectious Disease

Neoplasms

Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism (D50-D89)

Endocrine, Nutritional and Metabolic Diseases (E00-E89)

Mental and Behavioural Disorders

Study ID

NCT05013944

Start date

Sep 1, 2021

Status verified date

Jan, 2024

Completion date

Aug 31, 2026

Anticipated

Primary completion date

Aug 31, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 18 years old or older;
  • Confirmed positive diagnosis of disease, condition or disorder. This will be self-reported or reported by the patient's provider, advocacy group or other patient representative;
  • Laboratory or other independent means of confirmation is not required but may be confirmed in clinical trials;
  • Able to understand and willing to sign the informed consent document; or whose legal representative has given consent to participate in the research per state and Federal requirements;
  • Willing and able to complete the registry questions or have the instrument(s) completed by an informed proxy;
  • Anticipated additional follow up with the registry once per year.

Exclusion Criteria:

  • Subjects who do not meet the inclusion criteria for the study;
  • Subjects who are unable to understand the protocol or unable to provide legally effective informed consent

Study Design

Enrollment

100000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Assess Natural history [ Time Frame: 5 years ]
  • Assess Clinical, Cost and/or Comparative Effectiveness [ Time Frame: 5 years ]
  • Assess Safety [ Time Frame: 5 years ]
  • Measuring and/or Improving Quality of Care [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Christopher Beardmore

+1 (224) 218-2408chris@anovaevidence.com

Locations

Anova Enterprises, Inc.

Recruiting

Arlington Heights, Illinois, United States, 60005

Contacts

Martin Walsh

224-218-2408info-us@anovaevidence.com

Principal Investigator:

Christopher Beardmore

More Information

Sponsor

Anova Enterprises, Inc

Last update posted

Jan 30, 2024

Last verified

Jan, 2024

Keywords

  • infectious disease, cancer/oncology, neurology, immunology, cardiology

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Anova Enterprises, Inc on 2024-01-30.